RxDoctor Payments Data

Jay Smith, MD

Family Medicine · Memphis, TNNPI 1316930944

Payments from drug & device makers

$14,352in general payments, 2019–2025

Across 791 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$3K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • Pfizer$842
  • AbbVie$601
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$14,26399%
  • Education$891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,352 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$152,322
Medicare patients
323
Services billed
4,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$31,966
JanuviaSitagliptin Phosphate23$31,575
JardianceEmpagliflozin40$29,071
FarxigaDapagliflozin Propanediol23$20,436
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$18,288
ArexvyRsvpref3 Antigen/As01e/Pf55$17,276
Janumet XrSitagliptin Phos/Metformin Hcl27$15,389
EliquisApixaban17$15,020
Breo ElliptaFluticasone/Vilanterol15$5,836
InvokanaCanagliflozin11$5,140
Ezetimibe144$3,794
SynthroidLevothyroxine Sodium40$3,314
Benicar HctOlmesartan/Hydrochlorothiazide11$3,127
Atorvastatin Calcium334$3,057
Rosuvastatin Calcium265$2,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr$572$46,96350 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,567$38,72539 claims
Novo NordiskOzempic$3,337$31,96625 claims
Boehringer IngelheimJardiance$600$29,07140 claims
GSKArexvy, Breo Ellipta$525$23,11270 claims
PfizerEliquis$842$15,02017 claims
Johnson & JohnsonInvokana$83$5,14011 claims
AbbVieSynthroid$601$3,31440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →